Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
  • Sign in
    My account
    Logout
AI 90-DAY FORECAST
BEARISH SIGNAL DETECTED
██.█% Sign up free to reveal

Sangamo Therapeutics, Inc (SGMOQ) AI Forecast

Our AI detected a significant signal for Sangamo Therapeutics, Inc. Create a free account and follow it to see the exact price target.

✓ Free account • ✓ 30-day free trial

$SGMOQ Bearish Signal Full forecast available
Sign Up Free

Sangamo Therapeutics, Inc (SGMOQ) Stock Forecast 2025

Sangamo Therapeutics, Inc (SGMOQ) AI Stock Price Forecast & Investment Analysis

Sangamo Therapeutics, Inc Stock Price Chart and Technical Analysis

Loading chart...

Sangamo Therapeutics, Inc (SGMOQ) - Comprehensive Stock Analysis & Investment Research

Deep dive into Sangamo Therapeutics, Inc's business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on July 27, 2026, 2:56 p.m. (UTC)

Sangamo Therapeutics, Inc Investment Summary

When evaluating whether Sangamo Therapeutics, Inc (SGMOQ) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Sangamo Therapeutics, Inc (SGMOQ) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry. . With a market capitalization of $27 million, the company is a small-cap stock that may offer higher growth potential but also carries higher volatility.

Financial Performance Analysis

Our comprehensive financial analysis covers Sangamo Therapeutics, Inc's revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Sangamo Therapeutics, Inc along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Sangamo Therapeutics, Inc is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Sangamo Therapeutics, Inc

Sign Up Free
Corporate Identity

Sangamo Therapeutics, Inc (Stock Symbol: SGMOQ) is a prominent company operating within the Life Sciences sector, with a specific focus on the Biological Products, (No Diagnostic Substances) industry. The company's shares are publicly traded on the OTC exchange.

Leadership & Workforce

Detailed information about Sangamo Therapeutics, Inc's leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Sangamo Therapeutics, Inc...

Sector & Industry Analysis

In-depth sector dynamics and industry context for Sangamo Therapeutics, Inc...

Unlock Full Company Profile

Get complete details about Sangamo Therapeutics, Inc

Sign Up Free
Revenue & Growth Analysis

Sangamo Therapeutics, Inc generates annual revenues of $34 million , representing an emerging company in its growth phase.

Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Sangamo Therapeutics, Inc...

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Sangamo Therapeutics, Inc...

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Sangamo Therapeutics, Inc...

Unlock Financial Analysis

Get complete financial metrics for Sangamo Therapeutics, Inc

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Sangamo Therapeutics, Inc's AI Price Forecast

Join 10,000+ investors using our 67%+ accurate AI predictions

4,000+ Stocks Analyzed
67%+ Accuracy Rate
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Sangamo Therapeutics, Inc strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace. As a small-cap company, it represents an emerging market participant with potentially significant growth opportunities. Small-caps often offer greater growth potential as they capture market share and scale their operations, though this comes with higher risk and volatility. Success at this stage can lead to substantial returns for early investors who identify winning business models.

Industry Competitive Landscape

Sangamo Therapeutics, Inc competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency

The company currently shows negative free cash flow of $-90 million . Negative free cash flow may reflect heavy investment in growth, working capital needs, or operational challenges. This is common for high-growth companies investing aggressively but warrants attention for mature businesses.

Asset Utilization Efficiency

Asset turnover ratio of 0.58x indicates moderate asset turnover common in capital-intensive industries such as utilities, real estate, or heavy manufacturing. Lower turnover in these sectors is expected due to the significant infrastructure required for operations.

Financial Strength & Leverage

Current ratio of 0.70 reflects potential liquidity concerns with current liabilities exceeding current assets. While some businesses operate successfully with negative working capital, this warrants understanding of the specific circumstances.

Sangamo Therapeutics, Inc (SGMOQ) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Sangamo Therapeutics, Inc stock analysis.

Deep dive into Sangamo Therapeutics, Inc's financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Sangamo Therapeutics, Inc stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Sangamo Therapeutics, Inc:

Market Cap $27M
Revenue/Share $0.09
FCF/Share $-0.23
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Sangamo Therapeutics, Inc converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Sangamo Therapeutics, Inc: An ROE of 418.6% demonstrates excellent shareholder value creation.

ROE 418.6%
ROA -132.3%
ROIC -1164.2%
Operating Margin -535.3%
Net Margin -534.1%
EBT Margin -535.3%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Sangamo Therapeutics, Inc's ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Sangamo Therapeutics, Inc: A current ratio of 0.70 suggests potential liquidity concerns.

Current Ratio 0.70x
D/E Ratio -4.16x
Financial Leverage -3.16x
Working Capital -$16M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Sangamo Therapeutics, Inc's ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Sangamo Therapeutics, Inc: Free cash flow of $-90M indicates cash challenges that need attention.

Operating Cash Flow -$78M
Free Cash Flow -$90M
Capital Spending -$13M
FCF/Sales -261.8%
CapEx/Sales 36.9%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Sangamo Therapeutics, Inc uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Sangamo Therapeutics, Inc: An asset turnover of 0.58x suggests room for improvement in asset utilization.

Asset Turnover 0.58x
Receivables Turnover 39.6x
Fixed Assets Turnover 3.4x
Days Sales Outstanding 9 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Sangamo Therapeutics, Inc's income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Sangamo Therapeutics, Inc: With annual revenue of $34M, Sangamo Therapeutics, Inc represents a smaller but potentially high-growth operation.

Income Statement
Total Revenue $34M
Operating Income -$79M
Net Income -$79M
R&D Expense $66M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 37%
Cash & Short-term Investments 28%
Total Liabilities 79%
Short-term Debt 34%
Accounts Receivable 1%
Dividend & Shareholder Information
Shares Outstanding 390M
Growth Metrics (YoY)
Net Income Growth -534.1%

Latest Sangamo Therapeutics, Inc Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Sangamo Therapeutics, Inc (SGMOQ) stock price and investment outlook.

📰 Loading...

Sangamo Therapeutics, Inc Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of Sangamo Therapeutics, Inc against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
ABOS ██% $157M x 1.8x
ABPO ██% $1M x x
ACOG ██% $179M x 3.1x
ADAPY ██% $8M x x
ADMA ██% $1.94B 11.8x 5.0x
ADPT ██% $3.56B x 16.5x
AGEN ██% $238M 3.7x x
AGTX ██% $800K x x
AIM ██% $7M x 3.3x
ALEC ██% $165M x 15.9x
ALGS ██% $29M x 0.9x
ALLO ██% $628M x 2.3x
ALVO ██% $992M x x
AMGN ██% $200.50B 25.7x 21.8x
APGE ██% $10.05B x x
APTOF ██% $4M x x
ARGX ██% $57.22B x x
ARMP ██% $192M x x
ARTV ██% $492M x 5.6x
ATRA ██% $70M x x
ATYR ██% $49M x 0.8x
AURA ██% $745M x 6.9x
AUTL ██% $405M x 3.7x
AVXL ██% $230M x 1.8x
BCAB ██% $6M x x
BCDA ██% $14M x x
BCLI ██% $11M x x
BCRX ██% $2.38B x x
BDTX ██% $105M x 1.0x
BEAM ██% $2.66B x 2.3x
BIIB ██% $29.53B 21.5x 1.6x
BNTX ██% $23.28B x x
CABA ██% $444M x 4.3x
CADL ██% $722M x 5.2x
CCCC ██% $380M x 1.6x
CELZ ██% $5M x 0.9x
CERO ██% $500K x x
CGEM ██% $1.06B x 2.9x
CGEN ██% $221M 3.1x 2.2x
CGON ██% $6.26B x 5.7x
CGTX ██% $86M x 2.9x
CHRS ██% $221M 1.2x 2.8x
CLDI ██% $2M x 0.4x
CLLS ██% $279M x x
CMPX ██% $382M x 2.1x
CPMV ██% $5M x x
CRDF ██% $65M x 1.9x
CRDL ██% $123M x x
CRIS ██% $9M x 0.7x
CRSP ██% $4.58B x 2.5x
CSBR ██% $83M x 19.5x
CVM ██% $21M x 3.0x
DBVT ██% $820M x 5.1x
DNA ██% $489M x 1.1x
DNLI ██% $3.72B x 4.0x
DTIL ██% $189M x 2.5x
DYAI ██% $44M x x
EDIT ██% $419M x 95.0x
ELUT ██% $40M 0.8x 1.8x
ENGN ██% $127M x 0.5x
ENTX ██% $99M x 9.3x
ENZN ██% $59M x 0.3x
ESLA ██% $32M x x
EVAX ██% $25M x x
EXEL ██% $14.12B 16.9x 7.3x
EXOZ ██% $40M x 26.1x
FATE ██% $293M x 1.6x
FDMT ██% $543M x 1.2x
FENC ██% $351M x 9.3x
GILD ██% $162.53B 17.6x 6.9x
GLUE ██% $1.94B x 3.7x
GNTA ██% $80M x 6.4x
GPLB ██% $260K x x
GRML ██% $30M x 0.6x
HALO ██% $9.58B 27.5x 43.6x
HUMA ██% $172M x 14.8x
IBRX ██% $7.75B x x
IKT ██% $366M x 2.2x
IMA ██% $63M x 0.5x
IMCR ██% $1.81B x 4.6x
IMTX ██% $1.25B x x
IMVT ██% $8.03B x 9.4x
INAB ██% $12M x 0.5x
INKT ██% $50M x x
INMB ██% $46M x 2.3x
INTS ██% $11M x 1.1x
IOVA ██% $2.25B x 3.1x
IPSC ██% $391M x 1.5x
IVVD ██% $172M x 0.9x
JATT ██% $88M x 0.4x
JSPR ██% $24M x 7.1x
KLRS ██% $90M x 1.3x
KOD ██% $2.55B x 22.7x
KRYS ██% $9.64B 42.8x 7.6x
KYMR ██% $9.07B x 5.9x
KYTX ██% $441M x 2.3x
LCTX ██% $267M x 5.0x
LENZ ██% $158M x 0.6x
LIFE ██% $1.87B x 32.2x
LIMN ██% $7M x x
LONA ██% $68M x 1.4x
LXEO ██% $349M x 1.5x
MAZE ██% $1.53B x 4.5x
MESO ██% $2.09B x x
MGTX ██% $986M x x
MGX ██% $46M x 0.3x
MOLN ██% $160M x x
MRNA ██% $22.64B x 3.1x
NBIX ██% $17.52B 26.2x 5.1x
NMRA ██% $281M x 4.0x
NVAX ██% $1.29B x x
OCGN ██% $430M x 74.0x
OTLK ██% $247M x x
PALI ██% $338M x 2.7x
PASG ██% $16M x 1.3x
PCVX ██% $8.03B x 2.7x
PHGE ██% $2M x x
PLUR ██% $19M x x
PLX ██% $189M 12.3x 2.8x
PMCB ██% $6M x 0.2x
PRME ██% $536M x 7.0x
PROK ██% $459M x x
PTHS ██% $96M x 2.7x
QGEN ██% $8.99B x 2.4x
QNCX ██% $18M 2.1x 1.1x
REPL ██% $865M x 5.2x
RGEN ██% $7.76B 151.0x 3.7x
RGNX ██% $656M x 31.1x
RLAY ██% $4.14B x 6.5x
RVMD ██% $37.78B x 25.2x
RXRX ██% $1.60B x 1.6x
SABS ██% $274M x 1.2x
SANA ██% $866M x 7.3x
SCLX ██% $52M x x
SCNI ██% $1M x 0.2x
SGMO ██% $29M x x
SGMOQ ██% $27M x x
SLDB ██% $804M x 2.2x
SLXN ██% $3M x 8.7x
SNTI ██% $13M x 5.2x
SRRK ██% $5.89B x 21.4x
SRZN ██% $231M x x
STRO ██% $391M x x
TARA ██% $226M x 1.3x
TARS ██% $2.52B x 7.2x
TCRX ██% $52M x 0.5x
TECH ██% $11.23B 102.5x 5.4x
TECX ██% $594M x 2.6x
TIL ██% $48M x 0.4x
TNYA ██% $168M x 1.6x
TSHA ██% $1.67B x 7.9x
TVGN ██% $18M x x
TWST ██% $5.75B x 12.6x
VACH ██% $541M 80.4x x
VALN ██% $488M x x
VCEL ██% $2.30B 107.1x 6.5x
VIR ██% $1.51B x 1.9x
VIVS ██% $2M x 0.4x
VOR ██% $1.03B x x
VXRT ██% $121M 3.3x 1.3x
VYGR ██% $186M x 1.1x
WINT ██% $340K x x
XFOR ██% $376M x 2.2x
ZEOX ██% $14M x 19.4x
ZIVO ██% $19M x x
ZURA ██% $502M x 2.3x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Sangamo Therapeutics, Inc Stock Forecast

How accurate are Sangamo Therapeutics, Inc stock predictions?

Our AI model shows a 15% Spearman correlation coefficient for SGMOQ predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Sangamo Therapeutics, Inc stock price forecasts?

Our analysis considers Sangamo Therapeutics, Inc's financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Sangamo Therapeutics, Inc a good investment in 2025?

Based on our AI analysis, Sangamo Therapeutics, Inc shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Sangamo Therapeutics, Inc forecasts updated?

Sangamo Therapeutics, Inc stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want a simpler view of Sangamo Therapeutics, Inc?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...